Flagship Harbor Advisors LLC Raises Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Flagship Harbor Advisors LLC raised its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 65.5% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,667 shares of the medical device company's stock after buying an additional 3,825 shares during the period. Flagship Harbor Advisors LLC's holdings in DexCom were worth $660,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Larson Financial Group LLC grew its stake in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after purchasing an additional 137 shares in the last quarter. Nia Impact Advisors LLC boosted its holdings in DexCom by 1.4% in the fourth quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock valued at $766,000 after purchasing an additional 140 shares in the last quarter. Level Four Advisory Services LLC increased its stake in DexCom by 1.1% in the fourth quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock valued at $1,026,000 after purchasing an additional 150 shares during the last quarter. Covestor Ltd increased its stake in DexCom by 15.6% in the fourth quarter. Covestor Ltd now owns 1,109 shares of the medical device company's stock valued at $86,000 after purchasing an additional 150 shares during the last quarter. Finally, TD Private Client Wealth LLC raised its holdings in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after purchasing an additional 167 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 6,184 shares of the stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the sale, the executive vice president now directly owns 109,621 shares of the company's stock, valued at approximately $9,329,843.31. This represents a 5.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael Jon Brown sold 10,000 shares of DexCom stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $84.28, for a total transaction of $842,800.00. Following the transaction, the executive vice president now owns 95,602 shares of the company's stock, valued at approximately $8,057,336.56. The trade was a 9.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 25,724 shares of company stock worth $2,157,034 in the last quarter. Company insiders own 0.32% of the company's stock.

DexCom Price Performance

Shares of NASDAQ:DXCM traded down $2.89 on Wednesday, reaching $84.68. 4,198,343 shares of the company were exchanged, compared to its average volume of 4,383,063. The company has a 50-day moving average of $80.70 and a 200-day moving average of $79.46. The company has a current ratio of 1.50, a quick ratio of 1.32 and a debt-to-equity ratio of 0.55. The firm has a market cap of $33.20 billion, a price-to-earnings ratio of 63.19, a price-to-earnings-growth ratio of 1.70 and a beta of 1.46. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $117.19.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The company had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. During the same period in the prior year, the firm posted $0.32 EPS. The firm's quarterly revenue was up 12.5% on a year-over-year basis. Equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of recent analyst reports. Robert W. Baird dropped their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Citigroup reiterated a "buy" rating and set a $102.00 target price (up previously from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Canaccord Genuity Group boosted their target price on DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Mizuho started coverage on DexCom in a research note on Thursday, April 10th. They set an "outperform" rating and a $85.00 price target on the stock. Finally, Cfra Research raised DexCom to a "hold" rating in a research report on Friday, March 21st. Four equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $98.50.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.